Sotera Health (NASDAQ:SHC) Stock Holdings Decreased by Nuveen Asset Management LLC

Nuveen Asset Management LLC trimmed its position in Sotera Health (NASDAQ:SHC - Free Report) by 7.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 406,655 shares of the company's stock after selling 30,861 shares during the quarter. Nuveen Asset Management LLC owned approximately 0.14% of Sotera Health worth $5,563,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in the company. Blue Trust Inc. grew its holdings in shares of Sotera Health by 164.3% during the fourth quarter. Blue Trust Inc. now owns 1,834 shares of the company's stock valued at $25,000 after purchasing an additional 1,140 shares during the last quarter. Quarry LP acquired a new position in Sotera Health during the 4th quarter valued at approximately $28,000. Tower Research Capital LLC TRC grew its stake in Sotera Health by 37.8% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,975 shares of the company's stock worth $82,000 after buying an additional 1,640 shares during the last quarter. Sterling Capital Management LLC grew its stake in Sotera Health by 58.5% during the 4th quarter. Sterling Capital Management LLC now owns 9,029 shares of the company's stock worth $124,000 after buying an additional 3,331 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Sotera Health by 39.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,302 shares of the company's stock worth $127,000 after buying an additional 2,627 shares during the period. 91.03% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

SHC has been the subject of several analyst reports. Piper Sandler reduced their price target on shares of Sotera Health from $15.00 to $13.00 and set a "neutral" rating for the company in a report on Wednesday, April 23rd. The Goldman Sachs Group raised Sotera Health from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $14.00 to $17.00 in a report on Monday, May 5th. Finally, Barclays cut their target price on Sotera Health from $16.00 to $12.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.80.

Sotera Health Price Performance

NASDAQ:SHC traded up $0.08 during midday trading on Wednesday, hitting $12.36. 105,971 shares of the stock were exchanged, compared to its average volume of 1,195,070. Sotera Health has a one year low of $9.53 and a one year high of $17.08. The company has a market capitalization of $3.51 billion, a price-to-earnings ratio of 49.74 and a beta of 1.88. The business has a 50-day moving average price of $11.69 and a two-hundred day moving average price of $12.57. The company has a current ratio of 2.88, a quick ratio of 2.61 and a debt-to-equity ratio of 4.91.

Sotera Health (NASDAQ:SHC - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.12 by $0.02. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The firm had revenue of $254.52 million for the quarter, compared to analysts' expectations of $245.56 million. During the same period in the previous year, the business earned $0.13 earnings per share. Sotera Health's revenue for the quarter was up 2.6% compared to the same quarter last year. Sell-side analysts predict that Sotera Health will post 0.61 EPS for the current year.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.